

FDA OKs expanded platelet safety measure testing, 7/15

July 2015—Verax Biomedical has gained FDA clearance to expand the use of its Verax Platelet PGD test—a rapid test for the detection of bacterial contamination in platelets intended for transfusion. The test is an immunoassay used on the day of transfusion at the point of care, a hospital or transfusion service, to quickly detect bacterial contamination in platelets and protect patients from receiving contaminated transfusions.

The test can be used to check apheresis platelets in plasma and whole blood derived platelets, and with this FDA clearance, it can be used as a safety measure to check two additional platelet types: pre-storage pool platelets (e.g. Acrodose platelets) and apheresis platelets in PAS-C additive solution and plasma.

[Verax Biomedical](#), 508-755-7029